The Egyptian Ministry of Health and Population is tightening its grip on the pharmaceutical sector with a two-pronged approach through a new drug pricing review committee and an expanded review capacity at the Egyptian Drug Authority.
Ministry spokesperson Hossam Abdel Ghaffar announced the formation of the committee, chaired by Health Minister Khaled Abdel Ghaffar, during a recent medical conference in Cairo.
This committee will meet every six months to ensure fair and transparent drug pricing.
The initiative comes amid concerns about potential drug shortages, highlighting the government’s commitment to making essential medications affordable and accessible.
To expedite the pricing review process, the Egyptian Drug Authority is also ramping up its efforts. They plan to significantly increase the number of drug classes evaluated each week, allowing for a quicker response to price changes in the market.
These proactive measures are expected to bring greater transparency and stability to Egypt’s pharmaceutical sector, benefiting both patients and the healthcare system alike.
